Relapsed Wegener's granulomatosis after rituximab therapy - B cells are present in new pathological lesions despite persistent 'depletion' of peripheral blood

Nephrology Dialysis Transplantation

Volumn 23, Issue 9, 2008, Pages 3030-3032

  Ferraro, Alastair J ^a   Smith, Stuart W ^a   Neil, Desley ^b   Savage, Caroline O S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

B cell depletion; Monitoring; Rituximab; Vasculitis

Indexed keywords

CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; UNCLASSIFIED DRUG; VIGAM; VORICONAZOLE;

AGED; ARTICLE; B LYMPHOCYTE; BLOOD; CASE REPORT; CLINICAL FEATURE; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; PATHOGENESIS; PATHOLOGY; PRIORITY JOURNAL; RELAPSE; WEGENER GRANULOMATOSIS;

AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; B-LYMPHOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC FACTORS; LUNG; LYMPHOCYTE DEPLETION; MALE; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; WEGENER GRANULOMATOSIS;

EID: 58149251788     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfn318     Document Type: Article

References (10)

1. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-445
2. Keogh KA, Wylam ME, Stone JH et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-268
3. Keogh KA, Ytterberg SR, Fervenza FC et al. Rituximab for refractory Wegener's granulomatosis. Report of a prospective, open label, pilot trial. Am J Respir Crit Care Med 2006; 173: 180-187
4. Smith KG, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2782
5. Harper L, Savage COS. Pathogenesis of ANCA-associated systemic vasculitis. J Pathol 2000; 190: 349-359
6. Aries PM, Hellmich B, Voswinkel J et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006; 65: 853-858
7. Omdal R, Wildhagen K, Hansen T et al. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005; 34: 229-232
8. Voswinkel J, Mueller A, Kraemer JA et al. B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions. Ann Rheum Dis 2006; 65: 859-864
9. Gong Q, Ou Q, Ye S et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immun 2005; 174: 817-826
10. Cambridge G, Stohl W, Leandro MJ et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B-cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006; 54: 723-732